@phdthesis{Geier2007,
  author    = {Geier, Christoph},
  title     = {BERAphon® versus Echo-Screen TDA : Vergleich zweier Untersuchungsger{\"a}te im universellen Neugeborenen-H{\"o}rscreening},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-25420},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2007},
  abstract  = {Universelles Neugeborenen H{\"o}rscreening ist die beste Methode fr{\"u}hestm{\"o}glich Kinder mit angeborenen H{\"o}rst{\"o}rungen zu identifizieren. Es wird in der vorliegenden Arbeit das BERAphon® mit dem Echo-Screen TDA verglichen. Beide Ger{\"a}te nutzen f{\"u}r das universelle Neugeborenen-H{\"o}rscreening die Hirnstammaudiometrie. Bei 5 von 226 Untersuchungsg{\"a}ngen war mit dem BERAphon® kein Screening m{\"o}glich, bei 10 von 226 Untersuchungsg{\"a}ngen war mit dem Echo-Screen TDA kein Screening m{\"o}glich. Der Unterschied ist bei einer Irrtumswahrscheinlichkeit von alpha < 0,05 statistisch nicht signifikant. Die Anzahl der auff{\"a}lligen Untersuchungen zur Nachuntersuchung war mit 12 von 213 Untersuchungen bei beiden Ger{\"a}ten gleich. Die Gesamtscreeningdauer bei 85 gemessenen Untersuchungen lag als Median mit dem BERAphon® bei 2 Minuten 40 Sekunden, mit dem Echo-Screen TDA bei 6 Minuten 18 Sekunden. Bei 68 Untersuchungen lieferte das BERAphon® schneller ein Ergebnis als der Echo-Schreen TDA. Bei 17 Untersuchungen lieferte der Echo-Screen TDA schneller ein Ergebnis als das BERAphon®. Der Unterschied ist bei einer Irrtumswahrscheinlichkeit von alpha < 0,05 statistisch signifikant. Wesentliche Unterschiede gibt es in der Bedienungsfreundlichkeit der Ger{\"a}te und beim Untersuchungskomfort f{\"u}r die Neugeborenen vor, w{\"a}hrend und nach dem Screening.},
  subject      = {Screening},
  language  = {de}
}
@article{DietrichGoetzeGeier2016,
  author    = {Dietrich, Christoph G. and G{\"o}tze, Oliver and Geier, Andreas},
  title     = {Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance},
  series = {World Journal of Gastroenterology},
  volume    = {22},
  journal   = {World Journal of Gastroenterology},
  number    = {1},
  doi       = {10.3748/wjg.v22.i1.72},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-191136},
  pages     = {72-88},
  year      = {2016},
  abstract  = {Liver cirrhosis is the common endpoint of many hepatic diseases and represents a relevant risk for liver failure and hepatocellular carcinoma. The progress of liver fibrosis and cirrhosis is accompanied by deteriorating liver function. This review summarizes the regulatory and functional changes in phase I and phase II metabolic enzymes as well as transport proteins and provides an overview regarding lipid and glucose metabolism in cirrhotic patients. Interestingly, phase I enzymes are generally downregulated transcriptionally, while phase II enzymes are mostly preserved transcriptionally but are reduced in their function. Transport proteins are regulated in a specific way that resembles the molecular changes observed in obstructive cholestasis. Lipid and glucose metabolism are characterized by insulin resistance and catabolism, leading to the disturbance of energy expenditure and wasting. Possible non-invasive tests, especially breath tests, for components of liver metabolism are discussed. The heterogeneity and complexity of changes in hepatic metabolism complicate the assessment of liver function in individual patients. Additionally, studies in humans are rare, and species differences preclude the transferability of data from rodents to humans. In clinical practice, some established global scores or criteria form the basis for the functional evaluation of patients with liver cirrhosis, but difficult treatment decisions such as selection for transplantation or resection require further research regarding the application of existing non-invasive tests and the development of more specific tests.},
  language  = {en}
}
@article{MetznerHerzogHeckeletal.2022,
  author    = {Metzner, Valentin and Herzog, Gloria and Heckel, Tobias and Bischler, Thorsten and Hasinger, Julia and Otto, Christoph and Fassnacht, Martin and Geier, Andreas and Seyfried, Florian and Dischinger, Ulrich},
  title     = {Liraglutide + PYY\(_{3-36}\) combination therapy mimics effects of Roux-en-Y bypass on early NAFLD whilst lacking-behind in metabolic improvements},
  series = {Journal of Clinical Medicine},
  volume    = {11},
  journal   = {Journal of Clinical Medicine},
  number    = {3},
  issn      = {2077-0383},
  doi       = {10.3390/jcm11030753},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-255244},
  year      = {2022},
  abstract  = {Background: Treatment options for NAFLD are still limited. Bariatric surgery, such as Roux-en-Y gastric bypass (RYGB), has been shown to improve metabolic and histologic markers of NAFLD. Glucagon-like-peptide-1 (GLP-1) analogues lead to improvements in phase 2 clinical trials. We directly compared the effects of RYGB with a treatment using liraglutide and/or peptide tyrosine tyrosine 3-36 (PYY\(_{3-36}\)) in a rat model for early NAFLD. Methods: Obese male Wistar rats (high-fat diet (HFD)-induced) were randomized into the following treatment groups: RYGB, sham-operation (sham), liraglutide (0.4 mg/kg/day), PYY\(_{3-36}\) (0.1 mg/kg/day), liraglutide+PYY\(_{3-36}\), and saline. After an observation period of 4 weeks, liver samples were histologically evaluated, ELISAs and RNA sequencing + RT-qPCRs were performed. Results: RYGB and liraglutide+PYY\(_{3-36}\) induced a similar body weight loss and, compared to sham/saline, marked histological improvements with significantly less steatosis. However, only RYGB induced significant metabolic improvements (e.g., adiponectin/leptin ratio 18.8 ± 11.8 vs. 2.4 ± 1.2 in liraglutide+PYY\(_{3-36}\)- or 1.4 ± 0.9 in sham-treated rats). Furthermore, RNA sequencing revealed a high number of differentially regulated genes in RYGB treated animals only. Conclusions: The combination therapy of liraglutide+PYY\(_{3-36}\) partly mimics the positive effects of RYGB on weight reduction and on hepatic steatosis, while its effects on metabolic function lack behind RYGB.},
  language  = {en}
}